Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Report First Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, April 18, 2007
Arena Pharmaceuticals to Report First Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, April 18, 2007 SAN DIEGO, April 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first
View HTML
Toggle Summary Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
- Analyses Estimate Humans Concentrate Lorcaserin in the Brain to a Much Lower Extent than Rats -<br>- Data to be Included in Response to Lorcaserin CRL -
View HTML
Toggle Summary Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
- Report to be Included in Response to Lorcaserin CRL -
View HTML
Toggle Summary Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California.
View HTML
Toggle Summary Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
-- Meeting Provides Additional Clarity on Next Steps Toward Approval --<br>-- Arena to Host Conference Call and Webcast at 8:30 a.m. Eastern Time Today --
View HTML
Toggle Summary Arena and Eisai Expand Marketing and Supply Agreement for Lorcaserin
New territories include Canada, Mexico and Brazil
View HTML
Toggle Summary Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available
View HTML
Toggle Summary Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN DIEGO , May 22, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being
View HTML
Toggle Summary Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
- Ongoing clinical programs remain on track with data readouts expected between 2020-21 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1bn as of March 31, 2020 SAN DIEGO , May 7, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results
- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or
View HTML